Navigation Links
Poniard Announces Positive Preliminary Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in First-Line Treatment of Colorectal Cancer
Date:6/1/2008

with the FOLPI regimen.

Current National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology for colon cancer encourage the discontinuation of FOLFOX after three months of therapy or sooner if significant neurotoxicity (Grade 3 or greater) develops.

About Picoplatin

Picoplatin has an improved safety profile relative to existing platinum-based cancer therapies and is designed to overcome platinum resistance associated with chemotherapy in solid tumors. It is being studied in multiple cancer indications, combinations and formulations. Picoplatin has been evaluated in more than 750 patients and has demonstrated anti-tumor activity in multiple indications with less severe kidney toxicity (nephrotoxicity) and nerve toxicity (neurotoxicity) than is commonly observed with other platinum chemotherapy drugs.

In addition to the ongoing Phase 2 clinical trial in CRC, Poniard is evaluating intravenous picoplatin in an ongoing pivotal Phase 3 trial, known as SPEAR (Study of Picoplatin Efficacy After Relapse), in small cell lung cancer. This registration trial currently is being conducted under a Special Protocol Assessment (SPA) from the U.S. Food and Drug Administration and is evaluating overall survival as the primary endpoint. Picoplatin is also being evaluated in an ongoing Phase 2 clinical trial in patients with metastatic hormone-refractory prostate cancer. Oral picoplatin is being evaluated in a Phase 1 clinical trial in solid tumors. The oral formulation of picoplatin has the same active pharmaceutical ingredient as the intravenous formulation. Picoplatin has not been approved by any regulatory authority for use in humans.

About Poniard Pharmaceuticals

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative oncology products to impact the lives of people with cancer. For additional information please visit

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
2. Poniard Pharmaceuticals Announces Updated Results of Picoplatin Phase 2 Trial Demonstrating Survival Benefit in Small Cell Lung Cancer Patients
3. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
4. Poniard Pharmaceuticals Initiates Randomized Phase 2 Trial of Picoplatin for First-Line Treatment of Metastatic Colorectal Cancer
5. Poniard Pharmaceuticals Provides Year-End Clinical Update at 2007 Lazard Capital Markets Healthcare Conference
6. Poniard Pharmaceuticals Announces Picoplatin Safety Data in Colorectal Cancer
7. Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients
8. Poniard Pharmaceuticals Announces Clinical Data From Picoplatin Oral Phase 1 to Be Presented at the American Association of Cancer Research Annual Meeting
9. Poniard Pharmaceuticals Announces Commercial Manufacturing Agreement With W. C. Heraeus GmbH for Picoplatin
10. Poniard Pharmaceuticals Announces Presentation of Clinical Data From Picoplatin Phase 2 Small Cell Lung Cancer Trial to be Presented at 1st IASLC-ESMO European Lung Cancer Conference
11. Poniard Pharmaceuticals Oral Picoplatin Demonstrates Positive Bioavailability in Ongoing Phase 1 Trial

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...wire/--AccordingtoMillenniumResearchGroup(MRG),the...ce,thenearly$3billionUSmarketfortraumafixationdevi...sdespitetherecenteconomicslowdown.MRG,s USMarketsf...lremainhighlydynamicoverthenextfiveyears,withcompe...erservedsegmentsofthetraumafixationmarket,fuelingm...
(Date:11/25/2009)...-Reportlinker.comannouncesthatanewmarketresearchre...ugDelivery-USMarketTrends&Analysis http://www...y---US-Market-Trends--Analysis.html ,, TheUSin...ftherapeuticapplicationsfromthedeliveryofconventio...rapeuticdrugs.Thefutureofthetechnologyhingesontoth...
(Date:11/24/2009)...ire-Asia/--ChindexInternational,Inc.,("Chindex")(N...fWestern,healthcareproductsandservicesinthePeople,...attendthe21stAnnualPiperJaffray,"Unplugged"HealthC...rkPalaceHotel. , Managementiscurrentlyschedul...dholdone-on-onemeetingsthroughouttheday.Awebcast,o...
Breaking Medicine Technology:US Trauma Fixation Device Market Not Seeing Signs of Slowdown 2US Trauma Fixation Device Market Not Seeing Signs of Slowdown 3Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 2Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 3Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 4Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 5Chindex International to Present at Piper Jaffray Health Care Conference 2Reportlinker Adds Novo Nordisk A S 3A PharmaVitae Profile 58967 1Reportlinker Adds Novo Nordisk A S 3A PharmaVitae Profile 58967 2Reportlinker Adds Novo Nordisk A S 3A PharmaVitae Profile 58967 3Reportlinker Adds Novo Nordisk A S 3A PharmaVitae Profile 58967 4Reportlinker Adds Novo Nordisk A S 3A PharmaVitae Profile 58967 5Wayne State University to Lead 246 25 Million NIH Research Program on One of the Most Common Inherited Neurological Disorders 3A Charcot Marie Tooth 58964 1Wayne State University to Lead 246 25 Million NIH Research Program on One of the Most Common Inherited Neurological Disorders 3A Charcot Marie Tooth 58964 2Wayne State University to Lead 246 25 Million NIH Research Program on One of the Most Common Inherited Neurological Disorders 3A Charcot Marie Tooth 58964 3Wayne State University to Lead 246 25 Million NIH Research Program on One of the Most Common Inherited Neurological Disorders 3A Charcot Marie Tooth 58964 4Immune Deficiency Foundation Among the First Rare Disease Patient Organizations to Launch Major Social Networking Initiatives 58961 1Immune Deficiency Foundation Among the First Rare Disease Patient Organizations to Launch Major Social Networking Initiatives 58961 2Immune Deficiency Foundation Among the First Rare Disease Patient Organizations to Launch Major Social Networking Initiatives 58961 3
(Date:11/25/2009)...stress increase blood pressure? This simple quest...y years. New Stress-related gene Modulates High B... blood pressure? This simple question has been th...ew research has for the first time established a l... pressure response to stress in mice as well as hu...
(Date:11/25/2009)...ab, already used to fight rheumatoid arthritis, co... , WEDNESDAY, Nov. 25 (HealthDay News) --...oma and rheumatoid arthritis now also shows some p...pe 1 diabetes. , The drug, rituximab (Rituxan),...insulin, even though the disease had destroyed som...
(Date:11/25/2009)..., forgetfulness could lead mothers to overlook nee.... 25 (HealthDay News) -- A mother,s depression can...found. , Their six-month study of 262 black mot...mothers had more depressive symptoms had more freq...th fewer depressive symptoms had less frequent ast...
(Date:11/25/2009)... positive note, CDC sees few signs of trouble with...25 (HealthDay News) -- The ongoing H1N1 swine flu ...s pneumonias among younger patients, a U.S. health...ncrease in serious pneumococcal infections around ...ational Center for Immunization and Respiratory Di...
(Date:11/25/2009)... ARLINGTON,Va.,Nov.25/PRNewswire-USNewswire/--TheA...tHealthCareFraudActof2009,"S.2128,whichisdesignedt...reventfraudinMedicare.ThebillwasintroducedbySen.Ge...everalprovisionstheAmericanAssociationforHomecareo...ssociationproposedtoCongressinFebruary.Thoseprovis...
Breaking Medicine News(10 mins):Health News:New stress-related gene modulates high blood pressure in mice and men 2Health News:Type 1 Diabetes May Have a New Foe 2Health News:Type 1 Diabetes May Have a New Foe 3Health News:Mom's Depression May Worsen Child's Asthma 2Health News:Swine Flu Tied to Rise in Pneumonias Among Young 2Health News:Swine Flu Tied to Rise in Pneumonias Among Young 3Health News:Swine Flu Tied to Rise in Pneumonias Among Young 4Health News:American Association for Homecare Endorses New U.S. Senate Bill, the 'Prevent Health Care Fraud Act of 2009' 2
... the meat, women go for the veggies , , WE...ary battle of the sexes, men are decidedly the car... new study finds. , Why the difference? Biology m...id L. Katz, director of the Prevention Research Ce...
...ers at the University of Pennsylvania School of Me...ed look at the molecular pathways underlying sleep...ricans, according to the National Institutes of He...ds of times a night. , The team found that in an...
...st Score in Comprehensive Report Comparing SSO and...Healthcare Industry, ANDOVER, Mass., March 19 Se...le Sign-On (SSO), announced today that it ranked #... Report (February, 2008) published by the healthca...
...ad scientific articles on drinking water treatment...this joint initiative of TU Delft and UNESCO-IHE i...ions, especially for researchers in developing cou...t ) journal for free; it is the author who pays fo...
... 19 In an Open,Letter to the Federal Drug Adminis...f the American Journal of Transplantation (AJT), t...he American Society of Transplant,Surgeons (ASTS) ...tter,s authors, described the letter as an appeal ...
...nd researchers will be at the forefront of fightin...he Australian Cancer Research Foundation (ACRF). ...s Diamantina Institute for Cancer, Immunology and ...s linked to cancer. , We will be able to sequenc...
Other Medicine News:Health News:The Gender Divide Starts Over Dinner 2Health News:The Gender Divide Starts Over Dinner 3Health News:Molecular biology of sleep apnea could lead to new treatments 2Health News:Sentillion Ranked #1 Vendor in KLAS' Single Sign-On & Context Management Report 2Health News:Sentillion Ranked #1 Vendor in KLAS' Single Sign-On & Context Management Report 3Health News:Free online scientific journal on drinking water 2
1-Day Acuvue
Magellan Mapper
Easygraph
Durasoft 3 Colors
Medicine Products: